Awakn Life Sciences Corp. (AWKNF)
| Previous Close | 0.1305 |
| Open | 0.1546 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1520 - 0.1546 |
| 52 Week Range | 0.0422 - 0.3370 |
| Volume | |
| Avg. Volume | 13,853 |
| Market Cap | 6.97M |
| Beta (5Y Monthly) | 2.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Canopy Growth secured $50M financing, and restructured debt with an institutional investor. High Tide appointed a new CFO, as the company eyes long-term growth. SNDL intends to move forward with Parallel and Skymint acquisitions, despites the deals facing litigation. Schwazze settled wage theft claims amidst another legal challenges. Key Takeaways; Psychedelic […]
NewsfileAwakn Life Sciences Discusses Filing of Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that, it intends to file its audited annual financial statements and MD&A for the financial year ended January 31, 2024 (the "Financial Statements") by May 30, 2024, in line with the standard timeli
NewsfileAwakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated April 3, 2024, it has closed a first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Offering")
